GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

BTIG analyst Ryan Zimmerman upgraded GE HealthCare stock to Buy from Hold. His new price target is $100, implying about 15% upside.

GE HealthCare Stock Is Rising. Why One Analyst Says Buy.

GE HealthCare's stock is ending a good week on a bad note on Friday, after its former parent, now known as GE Aerospace, took advantage of the recent rally to sell off about one half of its remaining stake.

GE HealthCare's stock pulls back after former parent sells off half its stake

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 15,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $86.00 per share. The Offering was upsized from the previously announced offering size of 10,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not recei.

GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 10,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Ae.

GE HealthCare Technologies Inc. Commences Secondary Offering of 10,000,000 Shares

GE Healthcare (NASDAQ: GEHC) stock price has bounced back in the past few months, helped by the overall recovery of American equities and the view that it is a bargain company. It rose to a high of $88.51 on Thursday, its highest level since April 29th.

GE Healthcare (GEHC) stock is a bargain – Morningstar

GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.

GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) announced the CE marks of its Vscan Air™ SL wireless handheld ultrasound system with Caption AI™ (Vscan Air SL with Caption AI), an artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care, as well as ECG-less Cardiac computed tomography (CT) scanning on its Revolution Apex™ platform, which allows clinicians to acquire cardiac images without the aid of the patients' electrocardiogram (ECG) signa.

GE HealthCare Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments at the Point of Care at ESC 2024

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today that management will present at the following September investor conferences. 2024 Wells Fargo Healthcare Conference in Boston on September 4, 2024 at 10:15 am ET/9:15 am CT Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, 2024 at 1:05 pm ET/12:05 pm CT These events can be accessed at the GE HealthCare Investor Relations website: https://investor.gehealthcare.com/news-events/events on the d.

GE HealthCare management to present at September investor conferences

GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.

GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of the MASTER trial results in the peer-reviewed journal Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration for surgical patients.1* End-tidal Control software automatically achieves and maintains clinician-set targets of end-tidal anesthetic agent and oxygen concentrations. The results highlight End-tidal Control's performance i.

Clinical Study Shows Targeted End-tidal Control Anesthesia Delivery Improves Efficiency and Accuracy to Help Optimize Patient Care

SAN DIEGO--(BUSINESS WIRE)--GE HealthCare today announced a collaboration with the University of California San Diego School of Medicine to investigate advanced magnetic resonance imaging (MRI) protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians. The goal of the project is to elevate women's pelvic health, filling an important gap in medical research and care. Its results have the potential to enable c.

GE HealthCare to Embark on a Collaboration to Elevate Women's Imaging

Clover Health Investments

Twist Bioscience Corp

Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

GE HealthCare Technologies, Inc. has good growth prospects with a healthy backlog, momentum in order growth, and easing year-over-year comparisons. Demand slowdown in China should prove temporary, with recovery expected as stimulus funding is disbursed, supporting overall sales growth. Margin improvement expected from volume leverage, high-margin new product innovations, and cost savings initiatives, leading to potential P/E multiple re-rating and stock upside.

GE HealthCare: Encouraging Long-Term Growth Prospects

GE HealthCare's Q2 earnings were disappointing, with revenue stagnating and cost efficiencies driving earnings, leading to a lowered price target and sell rating. The company continues to lag behind the market in various healthcare sectors, with AI potential diminishing and a decreased focus on R&D. Upside potential lies in the healthcare market and AI technology, but GEHC's slow progress and competition pose challenges for future growth.

GE HealthCare Q2 Earnings Recap (Rating Downgrade)

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Carolynne Borders - Chief Investor Relations Officer Peter Arduini - President & CEO Jay Saccaro - VP & CFO Conference Call Participants Joanne Wuensch - Citi Larry Biegelsen - Wells Fargo Anthony Petrone - Mizuho Group Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Matthew Taylor - Jefferies Graham Doyle - UBS Patrick Wood - Morgan Stanley Suraj Kalia - Oppenheimer Operator Good day, everyone, and thank you for standing by. Welcome to GE Healthcare's Second Quarter 2024 Earnings Conference Call.

GE HealthCare Technologies Inc. (GEHC) Q2 2024 Earnings Call Transcript

GE HealthCare (GEHC) shares rose over 4% in early trading Wednesday after the company reported second-quarter profits that beat analysts' estimates.

GE HealthCare Stock Surges as Profits Beat Estimates, Despite China Sales Headwinds

While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About GE HealthCare (GEHC) Q2 Earnings

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.92 per share a year ago.

GE HealthCare Technologies (GEHC) Tops Q2 Earnings Estimates

GE HealthCare posts adjusted earnings per share of $1 in the second quarter, higher than estimates of 98 cents.

GE HealthCare's Stock Is Dropping After Earnings Beat. Here's Why.

GE Healthcare cut its annual revenue growth forecast on Wednesday as it expects a slowdown in China sales, sending its shares down nearly 10% in trading before the bell.

GE Healthcare cuts revenue growth forecast for 2024, shares fall

Shares of GE Healthcare Technologies Inc. GEHC tumbled 9.3% in premarket trading Wednesday, after the medical technologies and diagnostics company reported second-quarter revenue that missed expectations and cash flow that was more negative. Net income rose to $428 million, or 93 cents a share, from $418 million, or 91 cents a share, in the same period a year ago.

GE Healthcare's stock tumbles after revenue miss, free cash flow turns more negative

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare President and CEO Peter Arduini said, “In the second quarter, we delivered year-over-year sales growth and margin expansion despite headwinds in the China market. We also reported solid orders growth with particular strength in the U.S., as healthcare systems invest in technologies that enhance patient care and improve productivity. We are pleased wit.

GE HealthCare reports second quarter 2024 financial results

Cencora Inc

Glaukos

DENTSPLY SIRONA

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

News for GE HealthCare Technologies Inc Stock (GEHC)